Search

Your search keyword '"Bataller, Alex"' showing total 299 results
Start Over Author "Bataller, Alex"
299 results on '"Bataller, Alex"'

2. Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

Author

Guerrero-Murillo, Mercedes, Rill-Hinarejos, Aina, Trincado, Juan L., Bataller, Alex, Ortiz-Maldonado, Valentín, Benítez-Ribas, Daniel, Español-Rego, Marta, González-Navarro, E Azucena, Martínez-Cibrián, Nuria, Marchese, Doménica, Martín-Martín, Lourdes, Martín García-Sancho, Alejandro, Rives, Susana, Heyn, Holger, Juan, Manel, Urbano-Ispizúa, Álvaro, Delgado, Julio, Orfao, Alberto, Mereu, Elisabetta, Bueno, Clara, and Menendez, Pablo

Published
2024
Full Text
View/download PDF

3. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Author

Bataller, Alex, Gener-Ricos, Georgina, Almanza-Huante, Emmanuel, Chien, Kelly S., Urrutia, Samuel, Bazinet, Alexandre, Rodriguez-Sevilla, Juan Jose, Hammond, Danielle, Sasaki, Koji, Takahashi, Koichi, DiNardo, Courtney D., Ravandi, Farhad, Borthakur, Gautam, Kadia, Tapan M., Kanagal-Shamanna, Rashmi, Kantarjian, Hagop M., Garcia-Manero, Guillermo, and Montalban-Bravo, Guillermo

Published
2024
Full Text
View/download PDF

4. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

Author

Bazinet, Alexandre, Garcia-Manero, Guillermo, Short, Nicholas, Alvarado, Yesid, Bataller, Alex, Abuasab, Tareq, Islam, Rabiul, Montalbano, Kathryn, Issa, Ghayas, Maiti, Abhishek, Yilmaz, Musa, Jain, Nitin, Masarova, Lucia, Kornblau, Steven, Jabbour, Elias, Montalban-Bravo, Guillermo, Rausch, Caitlin R, Pierce, Sherry, DiNardo, Courtney D, Kadia, Tapan, Daver, Naval, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Published
2024
Full Text
View/download PDF

5. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study

Author

Bataller, Alex, Montalban-Bravo, Guillermo, Bazinet, Alexandre, Alvarado, Yesid, Chien, Kelly, Venugopal, Sangeetha, Ishizawa, Jo, Hammond, Danielle, Swaminathan, Mahesh, Sasaki, Koji, Issa, Ghayas C, Short, Nicholas J, Masarova, Lucia, Daver, Naval G, Kadia, Tapan M, Colla, Simona, Qiao, Wei, Huang, Xuelin, Kanagal-Shamanna, Rashmi, Hendrickson, Stephany, Ravandi, Farhad, Jabbour, Elias, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

6. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Author

Bataller, Alex, Bazinet, Alexandre, DiNardo, Courtney D., Maiti, Abhishek, Borthakur, Gautam, Daver, Naval G., Short, Nicholas J., Jabbour, Elias J., Issa, Ghayas C., Pemmaraju, Naveen, Yilmaz, Musa, Montalban-Bravo, Guillermo, Takahashi, Koichi, Loghavi, Sanam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., and Kadia, Tapan M.

Published
2024
Full Text
View/download PDF

7. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Author

Oñate, Guadalupe, Pratcorona, Marta, Garrido, Ana, Artigas-Baleri, Alicia, Bataller, Alex, Tormo, Mar, Arnan, Montserrat, Vives, Susana, Coll, Rosa, Salamero, Olga, Vall-Llovera, Ferran, Sampol, Antònia, Garcia, Antoni, Cervera, Marta, Avila, Sara Garcia, Bargay, Joan, Ortín, Xavier, Nomdedéu, Josep F., Esteve, Jordi, and Sierra, Jorge

Published
2023
Full Text
View/download PDF

8. Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome

Author

Guijarro, Francesca, López-Guerra, Monica, Morata, Jordi, Bataller, Alex, Paz, Sara, Cornet-Masana, Josep Maria, Banús-Mulet, Antònia, Cuesta-Casanovas, Laia, Carbó, Josep Maria, Castaño-Díez, Sandra, Jiménez-Vicente, Carlos, Cortés-Bullich, Albert, Triguero, Ana, Martínez-Roca, Alexandra, Esteban, Daniel, Gómez-Hernando, Marta, Álamo Moreno, José Ramón, López-Oreja, Irene, Garrote, Marta, Risueño, Ruth M., Tonda, Raúl, Gut, Ivo, Colomer, Dolors, Díaz-Beya, Marina, and Esteve, Jordi

Published
2023
Full Text
View/download PDF

9. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan

Author

Guijarro, Francesca, Bataller, Alex, Diaz-Beyá, Marina, Garrido, Ana, Coll-Ferrà, Christelle, Vives, Susana, Salamero, Olga, Valcárcel, David, Tormo, Mar, Arnan, Montserrat, Sampol, Antònia, Castaño-Díez, Sandra, Martínez, Carmen, Suárez-Lledó, María, Fernández-Avilés, Francesc, Hernández-Boluda, Juan Carlos, Ribera, Josep Maria, Rovira, Montserrat, Brunet, Salut, Sierra, Jorge, and Esteve, Jordi

Published
2022
Full Text
View/download PDF

10. CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Author

Bueno, Clara, Barrera, Susana, Bataller, Alex, Ortiz-Maldonado, Valentín, Elliot, Natalina, O'Byrne, Sorcha, Wang, Guanlin, Rovira, Montse, Gutierrez-Agüera, Francisco, Trincado, Juan L., González-González, María, Morgades, Mireia, Sorigué, Marc, Bárcena, Paloma, Zanetti, Samanta Romina, Torrebadell, Montse, Vega-Garcia, Nerea, Rives, Susana, Mallo, Mar, Sole, Francesc, Mead, Adam J., Roberts, Irene, Thongjuea, Supat, Psaila, Bethan, Juan, Manel, Delgado, Julio, Urbano-Ispizúa, Alvaro, Ribera, Josep María, Orfao, Alberto, Roy, Anindita, and Menendez, Pablo

Published
2022
Full Text
View/download PDF

11. NPM1‐mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.

Author

Gener‐Ricos, Georgina, Bataller, Alex, Rodriguez‐Sevilla, Juan Jose, Chien, Kelly S., Quesada, Andres E., Almanza‐Huante, Emmanuel, Hammond, Danielle, Sasaki, Koji, DiNardo, Courtney, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Issa, Ghayas C., Short, Nicholas J., Kanagal‐Shamanna, Rashmi, Kantarjian, Hagop M., Garcia‐Manero, Guillermo, and Montalban‐Bravo, Guillermo

Subjects
*STEM cell transplantation, *BONE marrow, *MYELODYSPLASTIC syndromes, *OVERALL survival, *CLINICAL pathology
Abstract

Introduction: NPM1‐mutated (NPM1mut) myeloid neoplasms (MNs) with <20% bone marrow (BM) blasts (NPM1mut MNs<20) are uncommon, and their classification remains inconsistent. Methods: The clinicopathologic features of 54 patients with NPM1mut MNs <20 were evaluated and compared with wild‐type NPM1 MNs <20 and NPM1mut MNs≥20, respectively. Results: NPM1mut MNs had similar features regardless of blast percentage, except for higher IDH2 (29% vs 7%, p =.023) and FLT3 (70% vs 11%, p <.001) frequency in patients with ≥20% BM blasts. Thirty‐three (61%) patients with NPM1mut MNs <20 received low‐intensity chemotherapy (LIC) and 12 (22%) received intensive chemotherapy (IC). Higher complete remission rates (75% vs 27%, p =.006) and median overall survival (mOS) (not reached vs 30.4 months, p =.06) were observed with IC compared to LIC. Young patients (age <60 years) did not reach mOS either when treated with LIC or IC. Stem cell transplant was associated with increased survival only in patients treated with LIC (HR, 0.24; p =.025). No differences in mOS were observed by BM blast strata (32.2 months, not reached and 46.9 months for <10%, 10%–19%, and ≥20% blasts, p =.700) regardless of treatment modality (LIC: p =.900; IC: p =.360). Twenty‐three patients (43%) with NPM1mut MNs <20 had marrow blast progression to ≥20%. Conclusions: Overall, NPM1mut MNs define a unique entity independent of BM blast percentage. NPM1 mutations define a unique leukemia entity regardless of bone marrow blast percentage. Patients with NPM1‐mutated myeloid neoplasms benefit from intensive chemotherapy approaches even in the setting of low bone marrow blast percentage. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.

Author

Senapati, Jayastu, Kantarjian, Hagop M., Bazinet, Alexandre, Reville, Patrick, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Bataller, Alex, Jabbour, Elias, DiNardo, Courtney, Haddad, Fadi, Sasaki, Koji, Popat, Uday, Oran, Betul, Alousi, Amin M., Loghavi, Sanam, Shpall, Elizabeth, Garcia‐Manero, Guillermo, Ravandi, Farhad, and Kadia, Tapan M.

Subjects
STEM cell transplantation, ACUTE myeloid leukemia, OLDER patients, VENETOCLAX, SURVIVAL rate, HEMATOPOIETIC stem cell transplantation
Abstract

Background: Allogeneic stem cell transplantation (SCT) remains the best consolidative modality in most patients with acute myeloid leukemia (AML). Along with factors directly pertaining to SCT, pretransplantation disease control, performance status, and prior treatment‐related complications are important factors that affect posttransplantation survival outcomes. Methods: The authors compared the survival outcomes of patients ≥60 years of age treated on the phase 2 clinical trial of venetoclax (Ven) added to cladribine (CLAD) and low dose cytarabine (LDAC) alternating with azacitidine (CLAD/LDAC/Ven arm) (NCT03586609) who underwent allogeneic SCT in first remission to a retrospective cohort of patients ≥60 years of age who underwent SCT after intensive chemotherapy. Intensive chemotherapy was defined as the use of cytarabine >1 g/m2 and anthracyclines during induction/consolidation. Results: Thirty‐five patients at median age of 68 years in the CLAD/LDAC/Ven arm were compared to 42 patients at a median age of 62 years in the intensive therapy arm. The 2‐year relapse‐free survival was superior with CLAD/LDAC/Ven versus intensive chemotherapy (88% vs. 65%; p =.03) whereas the 2‐year overall survival (OS) was comparable (84% vs. 70%; p =.14). On a competing event analysis, the 2‐year cumulative incidence of relapse (CIR) was significantly lower with CLAD/LDAC/Ven versus intensive chemotherapy (2.9% vs. 17.2%, Gray's p =.049) whereas nonrelapse mortality was comparable (16.2% vs. 17.1%; p =.486). Conclusion: In conclusion, treatment with CLAD/LDAC/Ven was associated with favorable outcomes in older patients who underwent subsequent allogeneic SCT. The OS was comparable to that with intensive chemotherapy followed by allogeneic SCT, but the CIR rate was significantly lower. Older patients (≥60 years of age) with acute myeloid leukemia who underwent allogeneic stem cell transplantation after low‐intensity therapy on the phase 2 trial of venetoclax added to cladribine and low dose cytarabine alternating with azacitidine had promising survival outcomes that were comparable to a retrospective cohort of patients who underwent allogeneic stem cell transplantation after intensive chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. TP53 Y220C mutations in patients with myeloid malignancies.

Author

Gener-Ricos, Georgina, Bewersdorf, Jan P., Loghavi, Sanam, Bataller, Alex, Goldberg, Aaron D., Sasaki, Koji, Famulare, Christopher, Takahashi, Koichi, Issa, Ghayas C., Borthakur, Gautam, Kadia, Tapan M., Short, Nicholas J., Senapati, Jayastu, Carter, Bing Z., Patel, Keyur P., Kantarjian, Hagop, Andreeff, Michael, Stein, Eytan M., and DiNardo, Courtney D.

Subjects
NUCLEOTIDE sequencing, SOMATIC mutation, CORPORATE directors, TUMOR suppressor proteins, TRANSCRIPTION factors, CHRONIC leukemia
Abstract

This letter to the editor discusses the prevalence and characteristics of TP53 Y220C mutations in patients with myeloid malignancies. The study found that these mutations were detected in 4.8% of patients with TP53 mutated myeloid neoplasms, most of whom had myelodysplastic syndromes or acute myeloid leukemia. The study also identified other co-occurring mutations. The authors suggest that targeted therapies may hold promise in improving outcomes for patients with this mutation, but further research is needed to address other TP53 mutations. [Extracted from the article]

Published
2024
Full Text
View/download PDF

14. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

Author

Bataller, Alex, Garrido, Ana, Guijarro, Francesca, Oñate, Guadalupe, Diaz-Beyá, Marina, Arnan, Montserrat, Tormo, Mar, Vives, Susana, de Llano, María Paz Queipo, Coll, Rosa, Gallardo, David, Vall-Llovera, Ferran, Escoda, Lourdes, Garcia-Guiñon, Antonio, Salamero, Olga, Sampol, Antònia, Merchan, Brayan M., Bargay, Joan, Castaño-Díez, Sandra, Esteban, Daniel, Oliver-Caldés, Aina, Rivero, Andrea, Mozas, Pablo, López-Guerra, Mònica, Pratcorona, Marta, Zamora, Lurdes, Costa, Dolors, Rozman, Maria, Nomdedéu, Josep F., Colomer, Dolors, Brunet, Salut, Sierra, Jorge, and Esteve, Jordi

Published
2022
Full Text
View/download PDF

16. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL

Author

Zanetti, Samanta Romina, Velasco-Hernandez, Talia, Gutierrez-Agüera, Francisco, Díaz, Víctor M., Romecín, Paola Alejandra, Roca-Ho, Heleia, Sánchez-Martínez, Diego, Tirado, Néstor, Baroni, Matteo Libero, Petazzi, Paolo, Torres-Ruiz, Raúl, Molina, Oscar, Bataller, Alex, Fuster, José Luis, Ballerini, Paola, Juan, Manel, Jeremias, Irmela, Bueno, Clara, and Menéndez, Pablo

Published
2022
Full Text
View/download PDF

17. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions.

Author

Kugler, Eitan, primary, Dasdemir, Enes, additional, Wang, Bofei, additional, Bataller, Alex, additional, Dinardo, Courtney Denton, additional, Daver, Naval Guastad, additional, Yilmaz, Musa, additional, Short, Nicholas James, additional, Kadia, Tapan M., additional, Sasaki, Koji, additional, Bazinet, Alexandre, additional, Pierce, Sherry, additional, Reville, Patrick Kevin, additional, Ravandi-Kashani, Farhad, additional, and Abbas, Hussein, additional

Published
2024
Full Text
View/download PDF

18. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.

Author

Bazinet, Alexandre, primary, Dinardo, Courtney Denton, additional, Arani, Naszrin, additional, Bataller, Alex, additional, Rausch, Caitlin R, additional, Maiti, Abhishek, additional, Swaminathan, Mahesh, additional, Daver, Naval Guastad, additional, Kadia, Tapan M., additional, Ravandi-Kashani, Farhad, additional, Kantarjian, Hagop M., additional, Chraibi, Samy, additional, Decroocq, Justine, additional, Pascal, Laurent, additional, Lebon, Delphine, additional, Bonnet, Sarah, additional, Gauthier, Nicolas, additional, Pages, Arnaud, additional, De Botton, Stéphane, additional, and Willekens, Christophe, additional

Published
2024
Full Text
View/download PDF

20. Engraftment characterization of risk-stratified AML in NSGS mice

Author

Díaz de la Guardia, Rafael, Velasco-Hernandez, Talía, Gutiérrez-Agüera, Francisco, Roca-Ho, Heleia, Molina, Oscar, Nombela-Arrieta, Cesar, Bataller, Alex, Fuster, Jose Luis, Anguita, Eduardo, Vives, Susana, Zamora, Lurdes, Nomdedeu, Josep, Gómez-Casares, María Teresa, Ramírez-Orellana, Manuel, Lapillonne, Helene, Ramos-Mejia, Verónica, Rodríguez-Manzaneque, Juan Carlos, Bueno, Clara, Lopez-Millan, Belen, and Menéndez, Pablo

Published
2021
Full Text
View/download PDF

23. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups

Author

Bataller, Alex, primary, DiNardo, Courtney D., additional, Bazinet, Alexandre, additional, Daver, Naval G., additional, Maiti, Abhishek, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Sasaki, Koji, additional, Jabbour, Elias J., additional, Issa, Ghayas C., additional, Pemmaraju, Naveen, additional, Yilmaz, Musa, additional, Montalban‐Bravo, Guillermo, additional, Loghavi, Sanam, additional, Garcia‐Manero, Guillermo, additional, Ravandi, Farhad, additional, Kantarjian, Hagop M., additional, and Kadia, Tapan M., additional

Published
2024
Full Text
View/download PDF

24. Integrative single-cell multi-omics of CD19-CARposand CARnegT cells suggest drivers of immunotherapy response in B-cell neoplasias

Author

Guerrero-Murillo, Mercedes, primary, Rill-Hinarejos, Aina, additional, Trincado, Juan L., additional, Bataller, Alex, additional, Ortiz-Maldonado, Valentín, additional, Benitez-Ribas, Daniel, additional, Español, Marta, additional, González, Europa Azucena, additional, Martinez-Cibrian, Nuria, additional, Marchese, Doménica, additional, Martín-Martín, Lourdes, additional, Garcia-Sancho, Alejandro Martin, additional, Heyn, Holger, additional, Juan, Manel, additional, Urbano-Ispizúa, Álvaro, additional, Delgado, Julio, additional, Orfao, Alberto, additional, Mereu, Elisabetta, additional, Bueno, Clara, additional, and Menendez, Pablo, additional

Published
2024
Full Text
View/download PDF

25. 3083 – SINGLE CELL MULTIOMIC ANALYSIS OF CLONAL AND TRANSCRIPTIONAL PROGRAMS OF CD19 CAR T CELLS IN THE IMMUNOTHERAPY RESPONSE

Author

Murillo, Mercedes Guerrero, Rill-Hinarejos, Aina, Trincado, Juan L, Bataller, Alex, Ortiz-Maldonado, Valentin, Benitez-Ribas, Daniel, Español, Marta, González, Europa Azucena, Martinez-Cibrian, Nuria, Marchese, Doménica, Martín-Martín, Lourdes, Garcia-Sancho, Alejandro Martin, Heyn, Holger, Juan, Manel, Urbano-Ispizúa, Álvaro, Delgado, Julio, Orfao, Alberto, Mereu, Elisabetta, Bueno, Clara, and Menendez, Pablo

Published
2024
Full Text
View/download PDF

27. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis

Author

Gutiérrez-García, Gonzalo, Cibeira, María Teresa, Rovira, Montserrat, Fernández de Larrea, Carlos, Tovar, Natalia, Rodríguez-Lobato, Luis Gerardo, Rosiñol, Laura, Marín, Pedro, Solano-Vega, Julio, Suárez-Lledó, María, Bataller, Alex, Solano, María Teresa, de Llobet, Noemí, Domenech, Ariadna, Borràs, Nuria, Lozano, Miquel, Cid, Joan, Martínez, Carmen, Urbano-Ispizua, Álvaro, Esteve, Jordi, Carreras, Enric, Fernández-Avilés, Francesc, and Bladé, Joan

Published
2019
Full Text
View/download PDF

29. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban‐Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C., additional, Kadia, Tapan M., additional, Daver, Naval, additional, Tang, Guilin, additional, Quesada, Andres, additional, Patel, Keyur P., additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P., additional, Kantarjian, Hagop M., additional, Bhalla, Kapil, additional, Garcia‐Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D., additional

Published
2023
Full Text
View/download PDF

30. AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Patel, Keyur P, additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P, additional, Kantarjian, Hagop M, additional, Bhalla, Kapil, additional, Garcia-Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

31. MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Patel, Keyur P, additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P, additional, Kantarjian, Hagop M, additional, Bhalla, Kapil, additional, Garcia-Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

32. POSTER: MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Patel, Keyur P, additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P, additional, Kantarjian, Hagop M, additional, Bhalla, Kapil, additional, Garcia-Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

33. Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF

Author

Jiménez-Vicente, Carlos, primary, Martínez-Roca, Alexandra, additional, Pomares, Helena, additional, Castaño-Diez, Sandra, additional, Guijarro, Francesca, additional, López-Guerra, Mònica, additional, Bataller, Alex, additional, Esteban, Daniel, additional, Cortés-Bullich, Albert, additional, Pérez-Valencia, Amanda Isabel, additional, Guardia-Torrelles, Ares, additional, Zugasti, Inés, additional, Rovira, Montserrat, additional, Fernández-Avilés, Francesc, additional, Colomer, Dolors, additional, Arnan, Montserrat, additional, Diaz-Beyá, Marina, additional, and Esteve, Jordi, additional

Published
2023
Full Text
View/download PDF

34. POSTER: AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Patel, Keyur P, additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P, additional, Kantarjian, Hagop M, additional, Bhalla, Kapil, additional, Garcia-Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

35. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies

Author

Bataller, Alex, primary, Abuasab, Tareq, additional, McCall, David, additional, Wang, Wei, additional, Cuglievan, Branko, additional, Issa, Ghayas C., additional, Jabbour, Elias, additional, Short, Nicholas, additional, DiNardo, Courtney D., additional, Tang, Guilin, additional, Garcia-Manero, Guillermo, additional, Kantarjian, Hagop M., additional, and Sasaki, Koji, additional

Published
2023
Full Text
View/download PDF

36. P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS

Author

Urrutia, Samuel, primary, LI, Ziyi, additional, Almanza, Emmanuel, additional, Bataller, Alex, additional, Kanagal-Shamanna, Rashmi, additional, Senapati, Jayastu, additional, Sasaki, Koji, additional, Chien, Kelly, additional, Montalban-Bravo, Guillermo, additional, Dinardo, Courtney, additional, Borthakur, Gautam, additional, Bueso Ramos, Carlos, additional, Pierce, Sherry, additional, Kantarjian, Hagop, additional, and Garcia-Manero, Guillermo, additional

Published
2023
Full Text
View/download PDF

38. P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE

Author

Chien, Kelly, primary, Urrutia, Samuel, additional, LI, Ziyi, additional, Kanagal-Shamanna, Rashmi, additional, Almanza, Emmanuel, additional, Abuasab, Tareq, additional, Gener, Georgina, additional, Bataller, Alex, additional, Bazinet, Alexandre, additional, Montalban-Bravo, Guillermo, additional, Short, Nicholas, additional, Jabbour, Elias, additional, Kadia, Tapan, additional, Ravandi, Farhad, additional, Borthakur, Gautam, additional, Hammond, Danielle, additional, Swaminathan, Mahesh, additional, Sasaki, Koji, additional, Pierce, Sherry, additional, Kantarjian, Hagop, additional, and Garcia-Manero, Guillermo, additional

Published
2023
Full Text
View/download PDF

39. P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.

Author

Jimenez-Vicente, Carlos, primary, Guijarro, Francesca, additional, Lopez-Guerra, Monica, additional, Guardia-Torrelles, Ares, additional, Martínez Roca, Alexandra, additional, Bataller, Alex, additional, Esteban, Daniel, additional, Cortés, Albert, additional, Zugasti, Inés, additional, Munarriz, Daniel, additional, Colomer, Dolors, additional, Diaz-Beya, Marina, additional, and Esteve, Jordi, additional

Published
2023
Full Text
View/download PDF

40. P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

Author

Senapati, Jayastu, primary, Kantarjian, Hagop, additional, Bazinet, Alexandre, additional, Reville, Patrick, additional, Borthakur, Gautam, additional, Daver, Naval, additional, Dinardo, Courtney, additional, Bataller, Alex, additional, Jabbour, Elias, additional, Short, Nicholas, additional, R. Popat, Uday, additional, Majid Alousi, Amin, additional, Shpall, Elizabeth J., additional, Garcia-Manero, Guillermo, additional, Ravandi, Farhad, additional, and Kadia, Tapan, additional

Published
2023
Full Text
View/download PDF

41. S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA

Author

Bataller, Alex, primary, Bazinet, Alexandre, additional, Venugopal, Sangeetha, additional, Montalban-Bravo, Guillermo, additional, Alvarado, Yesid, additional, Chien, Kelly, additional, Issa, Ghayas, additional, Short, Nicholas, additional, Hammond, Danielle, additional, Masarova, Lucia, additional, Kadia, Tapan, additional, Kanagal-Shamanna, Rashmi, additional, Hendrickson, Stephany, additional, Ravandi, Farhad, additional, Jabbour, Elias, additional, Kantarjian, Hagop, additional, and Garcia-Manero, Guillermo, additional

Published
2023
Full Text
View/download PDF

42. P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE

Author

Urrutia, Samuel, primary, Chien, Kelly, additional, LI, Ziyi, additional, Bataller, Alex, additional, Almanza, Emmanuel, additional, Sasaki, Koji, additional, Montalban-Bravo, Guillermo, additional, Short, Nicholas, additional, Jabbour, Elias, additional, Kadia, Tapan, additional, Ravandi, Farhad, additional, Borthakur, Gautam, additional, Kanagal-Shamanna, Rashmi, additional, Bueso Ramos, Carlos, additional, Pierce, Sherry, additional, Kantarjian, Hagop, additional, and Garcia-Manero, Guillermo, additional

Published
2023
Full Text
View/download PDF

43. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial

Author

Bazinet, Alexandre, Kantarjian, Hagop, Bataller, Alex, Pemmaraju, Naveen, Borthakur, Gautam, Chien, Kelly, Alvarado, Yesid, Bose, Prithviraj, Jabbour, Elias, Yilmaz, Musa, DiNardo, Courtney, Issa, Ghayas, Montalban-Bravo, Guillermo, Short, Nicholas, Sasaki, Koji, Bull-Linderman, Debra, Daver, Naval, Garcia-Manero, Guillermo, Ravandi, Farhad, and Kadia, Tapan

Abstract

Patients with acute myeloid leukaemia have high rates of relapse, especially if they are unable to complete standard consolidation strategies or allogeneic haematopoietic stem-cell transplantation (HSCT). The phase 3 QUAZAR AML-001 study showed an overall survival benefit with oral azacitidine maintenance. The BCL2 inhibitor venetoclax is highly active in acute myeloid leukaemia and synergistic with azacitidine. We aimed to evaluate the efficacy and safety of low dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia.

Published
2024
Full Text
View/download PDF

44. Integrative single‐cell expression and functional studies unravels a sensitization to cytarabine‐based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.

Author

Velasco‐Hernandez, Talia, Trincado, Juan L., Vinyoles, Meritxell, Closa, Adria, Martínez‐Moreno, Alba, Gutiérrez‐Agüera, Francisco, Molina, Oscar, Rodríguez‐Cortez, Virginia C., Ximeno‐Parpal, Pau, Fernández‐Fuentes, Narcís, Petazzi, Paolo, Beneyto‐Calabuig, Sergi, Velten, Lars, Romecin, Paola, Casquero, Raquel, Abollo‐Jiménez, Fernando, de la Guardia, Rafael D., Lorden, Patricia, Bataller, Alex, and Lapillonne, Hélène

Published
2024
Full Text
View/download PDF

45. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation

Author

Gutiérrez-García, Gonzalo, Rovira, Montserrat, Magnano, Laura, Rosiñol, Laura, Bataller, Alex, Suárez-Lledó, María, Cibeira, María Teresa, de Larrea, Carlos Fernández, Garrote, Marta, Jorge, Sofia, Moreno, Ana, Rodríguez-Lobato, Luis Gerardo, Carreras, Enric, Díaz-Ricart, Maribel, Palomo, Marta, Martínez, Carmen, Urbano-Ispizua, Alvaro, Bladé, Joan, and Fernández-Avilés, Francesc

Published
2018
Full Text
View/download PDF

46. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations

Author

Urrutia, Samuel, primary, Li, Ziyi, additional, Almanza, Emmanuel, additional, Bataller, Alex, additional, Kanagal-Shamanna, Rashmi, additional, Senapati, Jayastu, additional, Sasaki, Koji, additional, Chien, Kelly, additional, Montalban-Bravo, Guillermo, additional, DiNardo, Courtney, additional, Borthakur, Gautam, additional, Bueso-Ramos, Carlos, additional, Pierce, Sherry, additional, Kantarjian, Hagop, additional, and Garcia-Manero, Guillermo, additional

Published
2023
Full Text
View/download PDF

47. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia

Author

Bataller, Alex, primary, Chien, Kelly S., additional, Sasaki, Koji, additional, Montalban-Bravo, Guillermo, additional, Kanagal-Shamanna, Rashmi, additional, Urrutia, Samuel, additional, Almanza-Huante, Emmanuel, additional, Gener-Ricos, Georgina, additional, Ravandi, Farhad, additional, Jabbour, Elias, additional, Kadia, Tapan, additional, Borthakur, Gautam, additional, and Garcia-Manero, Guillermo, additional

Published
2023
Full Text
View/download PDF

48. Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.

Author

Kadia, Tapan M., Ravandi, Farhad, Molica, Matteo, Bataller, Alex, Borthakur, Gautam, Daver, Naval, Jabbour, Elias, DiNardo, Courtney D., Pemmaraju, Naveen, Jain, Nitin, Ferrajoli, Alessandra, Ylimaz, Musa, Bose, Prithviraj, Tidwell, Rebecca Slack, Marx, Kayleigh R., Rausch, Caitlin R., Kanagal‐Shamanna, Rashmi, Wang, Sa, Islam, Rabiul, and Champlin, Richard

Published
2023
Full Text
View/download PDF

49. Performance of IPSS‐M in patients with myelodysplastic syndrome after hypomethylating agent failure.

Author

Urrutia, Samuel, Chien, Kelly S., Li, Ziyi, Bataller, Alex, Almanza, Emmanuel, Sasaki, Koji, Montalban‐Bravo, Guillermo, Short, Nicholas J., Jabbour, Elias, Kadia, Tapan M., Ravandi, Farhad, Borthakur, Gautam, Alvarado, Yesid, Daver, Naval, Kanagal‐Shamanna, Rashmi, Bueso‐Ramos, Carlos, Pierce, Sherry A., Kantarjian, Hagop, and Garcia‐Manero, Guillermo

Published
2023
Full Text
View/download PDF

50. Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly( ADP ‐ribose) polymerase proteins inhibitors for solid tumours

Author

Almanza‐Huante, Emmanuel, primary, Bataller, Alex, additional, Urrutia, Samuel, additional, Gener‐Ricos, Georgina, additional, Briski, Robert Edward, additional, Kanagal‐Shamanna, Rashmi, additional, Lu, Karen H., additional, Westin, Shannon N., additional, Yap, Timothy A., additional, Takahashi, Koichi, additional, Ravandi, Farhad, additional, Alvarado, Yesid, additional, Kadia, Tapan, additional, Sasaki, Koiji, additional, Kantarjian, Hagop M., additional, and Garcia‐Manero, Guillermo, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results